Mirailab Bioscience Inc. (Head Office: Chuo-ku, Tokyo), a company proud to be the leading provider of NMN products to supplement age-related decline in NAD⁺ levels, is pleased to announce that as of July 31, 2025, Mr. Noriaki Shimizu has been appointed as the new Representative Director, CEO, and CTO, succeeding former President Ms. Megumi Tanaka. Additionally, capital participation has been secured from NX Holdings Co., Ltd., funded by an investment fund managed by Creacion Capital, Inc.
Furthermore, Mr. Shimizu has also been appointed as the new Representative Director of our group companies Orient International Inc. (Chuo-ku, Tokyo), succeeding Mr. Keimaru Tanaka, and Bio Umbrella Inc. (Minato-ku, Tokyo), succeeding Mr. Mitsuhiro Hirota, as of the same date.
Mr. Keimaru Tanaka, who has led our group to date, will now serve as Honorary Chairman.
■ Profile of Noriaki Shimizu
2000: Ph.D. in Engineering, Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology
Former positions include:
・NEDO Fellow
・JSPS Research Fellow (PD)
・JSPS Researcher under International Collaborative Research Acceleration Program
・Visiting Researcher at Karolinska Institute, Sweden
Project Lecturer, Institute of Medical Science, The University of Tokyo
Joined Mirailab in 2019 as a Chief Researcher
Appointed CTO in 2022
Appointed Director and CTO in 2022
Also serves as a part-time lecturer at Tokyo Medical University
Appointed CEO/CTO in July 2025
Awards: Japan Endocrine Society Young Investigator Award (36th), Japan Steroid Hormone Society Young Investigator Award (1st)
■ About Our Group
Our group primarily focuses on the manufacture and sale of supplements, cosmetics, health test kits, research reagents, as well as NMN-related research, intellectual property acquisition, and consulting services for medical institutions.
We have established ourselves as a leading NMN company by successfully commercializing highly pure, safe, reliable, and stable NMN products recognized by industry experts. Our in-house research facilities ensure high quality.
■ About NMN
NMN (Nicotinamide Mononucleotide) is a metabolite of nicotinamide, a type of vitamin B3. It serves as a precursor to NAD⁺ (Nicotinamide Adenine Dinucleotide) and helps replenish declining NAD⁺ levels associated with aging. As health awareness increases, NMN demand is expected to grow further.
■ About Creacion Capital, Inc.
Creacion Capital is an independent private equity firm that invests in companies for growth and succession support.
They invest in companies with unique products and competitive advantages. Recognizing our strength in providing high-quality supplements, they have joined as capital participants.
With their support, we aim to enhance domestic and international marketing, expand e-commerce operations, strengthen management, and grow corporate value.
■ Conclusion
Having been recognized as an attractive investment opportunity, we will move forward under a new science-driven leadership, aiming for faster decision-making and greater value creation across all businesses.
We sincerely appreciate your continued support.
■ Contact
For inquiries regarding this matter:
Mirailab Bioscience Inc.
https://www.mirailab-bio.com/contact